Viatris (VTRS) Total Current Liabilities (2019 - 2026)
Viatris (VTRS) recorded quarterly Total Current Liabilities of $6.8 billion in Q1 2026, down 4.0% quarter-over-quarter from $7.1 billion in Q4 2025, and up 19.06% on a YoY basis from $5.7 billion in Q1 2025.
Viatris (VTRS) Total Current Liabilities (2019 - 2026) Analysis & Trends
Viatris' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $6.8 billion for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 19.06% year-over-year to $6.8 billion; the TTM figure through Mar 2026 stood at $6.8 billion (up 19.06% YoY), while the FY2025 annual figure was $7.1 billion, up 22.75% from the prior year.
- Total Current Liabilities was $6.8 billion for Q1 2026 at Viatris, down from $7.1 billion in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $9.6 billion in Q1 2022 to a low of $5.7 billion in Q1 2025.
- Historically, Total Current Liabilities has averaged $7.1 billion across 5 years, with a median of $7.1 billion in 2025.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities tumbled 36.66% in 2023, then rose 27.04% in 2024.
- A 5-year view of Total Current Liabilities shows it stood at $6.7 billion in 2022, then rose by 15.29% to $7.8 billion in 2023, then retreated by 25.69% to $5.8 billion in 2024, then grew by 22.75% to $7.1 billion in 2025, then fell by 4.0% to $6.8 billion in 2026.
- The last three Total Current Liabilities figures came in at $6.8 billion (Q1 2026), $7.1 billion (Q4 2025), and $7.4 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 13.53 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 2.05 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 831.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 1.66 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 599.50 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 333.17 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 618.78 Mn |
| 10 | Viatris | - | - | 1.16 Bn | 6.81 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.81 Bn |
| Dec 31, 2025 | 7.09 Bn |
| Sep 30, 2025 | 7.36 Bn |
| Jun 30, 2025 | 7.13 Bn |
| Mar 31, 2025 | 5.72 Bn |
| Dec 31, 2024 | 5.78 Bn |
| Sep 30, 2024 | 7.51 Bn |
| Jun 30, 2024 | 7.71 Bn |
| Mar 31, 2024 | 7.76 Bn |
| Dec 31, 2023 | 7.78 Bn |
| Sep 30, 2023 | 6.83 Bn |
| Jun 30, 2023 | 6.52 Bn |
| Mar 31, 2023 | 6.11 Bn |
| Dec 31, 2022 | 6.75 Bn |
| Sep 30, 2022 | 6.52 Bn |
| Jun 30, 2022 | 7.68 Bn |
| Mar 31, 2022 | 9.64 Bn |
| Dec 31, 2021 | 9.88 Bn |
| Sep 30, 2021 | 10.10 Bn |
| Jun 30, 2021 | 10.13 Bn |